Translational Research Program

The Translational Research Program (TRP) was formed to enhance the transfer of basic research findings to clinical usefulness. This program is geared towards translational medicine for blood cancers. For the 2026 application cycle we will only consider applications that adhere to the following submission guidelines:

• For small molecule compounds the application must have in vivo proof of concept (POC) in appropriate mouse models. Alternatively, based on the mechanism of action, an in vitro POC with patient-derived samples may be considered.
• For cellular or immunotherapies, in vivo POC would make for a stronger application. We acknowledge, however, that depending on the type of therapy being developed an in vitro POC may be more appropriate or necessary.

Funding of $750,000 USD over three years.